Algorithm of diuretics prescription in chronic heart failure: Diuver as loop diuretic of new generation


Cite item

Full Text

Abstract

Treatment of chronic heart failure (CHF) by diuretics begins only if the clinical signs of congestion in pulmonary circulation and systemic circulation. Thiazide and loop diuretics are mainly used. Effective and safe diuretic torasemide has additional effects of renin-angiotensin-aldosterone system blockage. It can improve of prognosis of patients with CHF, that why this modern diuretic is the drug of choice, especially during the long period treatment and clinical decomposition.

References

  1. Беленков Ю.Н., Б Мареев В.Ю. Принципы рационального лечения сердечной недостаточности. М., 2000. 266 с.
  2. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. М., 2006. 432 с.
  3. Виноградов А.В. Мочегонные средства в клинике внутренних болезней. М., 1969. 151 с.
  4. Мухарлямов Н.М., Мареев В.Ю. Лечение хронической сердечной недостаточности. М. 1985, 207 с.
  5. Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med 1994;154:1905-14.
  6. Patterson JH, Adams KF, Applefeld MM, et al. for the Torsemide Investigators Group. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Pharmacotherapy 1994;14:514-21.
  7. Brater DC. Diuretic therapy. N Engl J Med 1998;339:387-95.
  8. Национальные Рекомендации ВНОК И ОССН по диагностике и лечению ХСН (третий пересмотр) // Сердечная Недостаточность. 2009. Т. 10 № 2. С. 88-89.
  9. Jones PW, Greenstone M. Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2001;(1):CD002881.
  10. Philippi H, Bieber I, Reitter B. Acetazolamide treatment for infantile central sleep apnea. Drugs 2001;61(2):237-51.
  11. Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. Am J Respir Crit Care Med 2006;173(2):234-37.
  12. Brater DC, Chennavasin P, Seiwell R. Furosemide in patients with heart failure: shift in dose-response curves. Clin Pharmacol Ther 1980;28(2):182-86.
  13. Vasko MR, Cartwright DB, Knochel JP, et al. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985;102(3):314-18.
  14. Dormans TP, van Meyel JJ, Gerlag PG, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996;28(2):376-82.
  15. Kasama S, Toyama T, Hatori T, et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart 2006;92(10):1434-40.
  16. Kim EJ, Lee MG. Pharmacokinetics and pharmacodynamics of intravenous tоrasemide in mutant Nagase analbuminemic rats. Biopharm. Drug Dispos 2003;24(1):27-35.
  17. Lopez B, Querejeta R, Gonzalez A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004;43(11):2028-35.
  18. Brater D. Torasemid: pharmacokinetic and clinical efficacy. Eur J Heart Fail 2001;3(Suppl. G):19-24.
  19. Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001;111(7):513-20.
  20. Stroupe KT, Forthofer MM, Brater DC, et al. Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics 2000;17(5):429-40.
  21. Fortuno A, Muniz P, Ravassa S, et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension 1999;34(1):138-43.
  22. Yamato M, Sasaki T, Honda K, et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J 2003;67(5):384-90.
  23. Tsutamoto T, Sakai H, Wada A, <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ishikawa%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2004;44(11):2252-53.
  24. Lopez B, Gonzalez A, Beaumont J, et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. Am Coll Cardiol 2007;50(9):859-67.
  25. Lopez B, Querejeta R, Gonzalez A, et al. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009;53(2):236-42.
  26. Muller K, Gamba G, Jaquet F, et al. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV-efficacy and quality of life. Eur J Heart Fail 2003;5(6):793.
  27. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002;4(4):507-13.
  28. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). http: www.acc.org / qualityandscience / clinical / guidelines / failure / update / index. pdf.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media